CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 1,407 enrolled / 1,407 target
Drug / intervention
Bevacizumab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03737643
NCT03737643Phase 3ActiveUpdate Overdue (15.7/mo)Completion was 15mo ago
CompareCT.gov

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

AstraZeneca·interventional·Posted Nov 9, 2018·Updated Jun 9, 2026

In Brief

A Phase 3 clinical trial evaluating Bevacizumab, Durvalumab, and 4 other interventions for Advanced Ovarian Cancer. Active but no longer recruiting, targeting 1,407 participants across 214 sites in 20 countries.

Signals

Enrollment appears stalled

Detailed Summary

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Ovarian Cancer
CountriesAustria, Belgium, Brazil, Bulgaria, Canada, China, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Peru, Poland, Romania, South Korea, Spain, Turkey (Türkiye), United States
CollaboratorsEuropean Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc.

Timeline

Phase 3Active
201920202021202220232024202520262027
First PostedNov 9, 2018
Enrollment StartJan 4, 2019
Primary CompletionMar 17, 2025
Study CompletionDec 23, 2026
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 7.6 years ago

Arms & Interventions

Arm 1active_comparator

Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).

Drug: BevacizumabDrug: Placebo olaparibDrug: Durvalumab placeboDrug: Carboplatin+Paclitaxel
Arm 2experimental

Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.

Drug: BevacizumabDrug: DurvalumabDrug: Placebo olaparibDrug: Carboplatin+Paclitaxel
Arm 3experimental

Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.

Drug: BevacizumabDrug: DurvalumabDrug: OlaparibDrug: Carboplatin+Paclitaxel
tBRCAm cohortexperimental

Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.

Drug: BevacizumabDrug: DurvalumabDrug: OlaparibDrug: Carboplatin+Paclitaxel

Interventions

Bevacizumabdrug

Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.

Durvalumabdrug

Durvalumab by intravenous infusion

Olaparibdrug

Olaparib tablets

Placebo olaparibdrug

Placebo tablets to match olaparib

Durvalumab placebodrug

Matching placebo for intravenous infusion

Carboplatin+Paclitaxeldrug

Standard of care chemotherapy